TMX group

Revenues Up 35% Year to Date 2006 Over 2005

VANCOUVER, Nov. 29 /CNW/ - Response Biomedical Corporation (TSX-V: RBM,
OTCBB: RPBIF) announced today financial results for the third quarter ended
September 30, 2006. For a further discussion of the Company's financial
results for the three and nine months ended September 30, 2006, please refer
to the Company's complete set of unaudited financial statements and the
Company's Management Discussion & Analysis of Financial Condition and Results
of Operations, which will be made available on SEDAR at www.sedar.com and US
EDGAR at www.sec.gov.

<<
Third quarter operating highlights:
-   Recorded total revenues for the three and nine month periods ended
    September 30, 2006 of $1,435,815 and $3,296,365 respectively, an
    increase of 99% and 35% from the same periods in 2005.  In
    particular, clinical products revenue, primarily from cardiovascular
    products, for the three and nine month periods ended September 30,
    2006 increased 598% and 400% to $902,246 and $1,690,137, respectively
    from the same periods in 2005.
-   Launched in Japan a BNP Test used to assist in the diagnosis and
    management of congestive heart failure with Shionogi & Co. Ltd.
    Purchasing over 200 readers year-to-date for the launch;
-   Completed US distribution network for RAMP cardiovascular products,
    with the appointment of two additional exclusive US regional
    distributors, making RAMP Cardiac Tests available throughout the US;
-   Initiated trials at four leading clinical trial sites for the purpose
    of obtaining FDA clearance to market the RAMP NT-ProBNP Test in the
    US;
-   RAMP Anthrax Test certified as the first and only test approved for
    field use by AOAC International following independent evaluation
    sponsored by the US Department of Homeland Security; and
-   Continued scale up and purchase of additional manufacturing equipment
    to increase the Company's test manufacturing capacity to an estimated
    330,000 tests per month per shift and continued development of the
    Company's next generation RAMP Reader.
>>

"An important accomplishment has been the growth in the strategically
important clinical cardiac testing product line," said Bill Radvak, President
and CEO. "At the same time, we continue to invest in bringing new key products
to the market. Clinical trial enrolment has recently been completed at US
clinical trial sites for our RAMP NT-proBNP Test used for the diagnosis and
monitoring of congestive heart failure. We expect this test to further improve
the competitiveness of our cardiac menu. In addition, our infectious disease
products, tests for Staph A and Flu A/B, are being prepared for upcoming
clinical trials. Importantly, we continue to make significant progress on our
strategy to secure well-positioned marketing partners for our RAMP product
lines.

<<
Summary of Interim Results
(Expressed in 000's except per share data)
-------------------------------------------------------------------------
Fiscal Year 2006                    Year to date         Year to date
                                 September 30, 2005   September 30, 2006
-------------------------------------------------------------------------
Total Revenue                         $  3,296             $  2,446
-------------------------------------------------------------------------
Research and Development
 Costs                                $  3,784             $  2,473
-------------------------------------------------------------------------
Net Loss                              $  5,897             $  5,394
-------------------------------------------------------------------------
Loss per share
 (basic and diluted)                  $  (0.07)            $  (0.08)
-------------------------------------------------------------------------
Cash position                         $  2,458             $     29
-------------------------------------------------------------------------
Working Capital                       $  3,445             $ (1,510)
-------------------------------------------------------------------------
Weighted Average Common
 Shares Outstanding                     87,584               67,446
-------------------------------------------------------------------------
>>

Financial Overview:
For the three and nine month periods ended September 30, 2006, sales of
the clinical cardiac products increased 598% and 400%, while sales of
environmental West Nile Virus products decreased by 18% and 7% and sales of
biodefense products decreased by 20% and 57% respectively, as compared to the
corresponding periods in 2005. Total revenues for the three and nine month
periods ended September 30, 2006 were $1,435,815 and $3,296,365 respectively,
an increase of 99% and 35% from the same periods in 2005. Revenues from
product sales for the three and nine months ended September 30, 2006 were
$1,356,506 and $2,841,172 compared to $692,435 and $2,342,034 for the same
periods in 2005, an increase of approximately 96% and 21% respectively. For
the three and nine month periods ended September 30, 2006, the Company
reported a loss of $1,833,288 and $5,896,716 or $0.02 and $0.07 per share,
respectively compared to a loss of $1,933,580 and $5,393,883 or $0.03 and
$0.08 per share for the same periods in 2005. At September 30, 2006, the
Company had a working capital balance of $3,445,068, compared to $5,431,374 as
of June 30, 2006 and negative working capital of $2,905,552 as of December 31,
2005.

About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site
diagnostic tests for use with its portable RAMP Platform for clinical and
environmental applications. RAMP represents a new paradigm in diagnostics that
provides high sensitivity and reliable information in minutes. It is ideally
suited to both point-of-care testing and for laboratory use. The RAMP System
consists of a portable fluorescent Reader and single-use, disposable Test
Cartridges, and has the potential to be adapted to more than 250 medical and
non-medical tests currently performed in laboratories. RAMP tests are
commercially available for the early detection of heart attack and congestive
heart failure, environmental detection of West Nile virus, infectious disease
and biodefense applications including the rapid on-site detection of anthrax,
smallpox, ricin and botulinum toxin. Several other product applications are
under development. The Company has achieved CE Marking and its Quality
Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.
Response Biomedical is a publicly traded company, listed on the TSX
Venture Exchange under the trading symbol "RBM" and quoted on the OTC Bulletin
Board under the symbol "RPBIF". For further information, please visit the
Company's website at www.responsebio.com.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.

Note on Forward Looking Statements
Statements contained in this press release relating to future results,
events or developments, for example, statements containing the words
"believes," "may," "could", "plans," "will," "estimate," "continue,"
"anticipates," "intends," "expects", "goal" and similar expressions, are
"forward-looking statements" or "forward-looking information" under applicable
United States and Canadian securities laws. Forward-looking statements or
information may involve, but are not limited to, comments with respect to our
planned activities, business plan and strategies and their future
implementation, and our expectations for our financial condition and the
results of, or outlook for, our business operations generally. Forward-looking
statements or information are subject to the related assumptions made by us
and involve known and unknown risks, uncertainties and other factors that may
cause actual results, events or developments to be materially different from
those expressed or implied by such statements or information.
Many of such risks, uncertainties and other factors form part of our
underlying assumptions, and include, among other things, financial risks that
would affect our operations such as our available working capital and cash
flows and whether and for how long available funds will be sufficient to fund
our operations and our ability to raise additional capital as and when needed;
our need for substantial additional funding to conduct research and
development and commercialization activities; our ability to establish, and
our dependence upon, relationships with strategic alliance partners to develop
and commercialize products; technological changes that impact our existing
products or our ability to develop and commercialize our products; our ability
to obtain and enforce timely patent and other intellectual property protection
for our technology and products; our ability to obtain and maintain rights to
technology from licensors; liability for patent, product liability and other
claims asserted against us; commercialization limitations imposed by patents
owned or controlled by third parties; technical risk in research and
development; adverse results or unexpected delays in product development and
clinical trials; our ability to retain, and our reliance upon, third party
suppliers, manufacturers and distributors; our ability to attract and retain
qualified personnel; our ability to effectively and efficiently manage the
planned growth of our operations; our ability to obtain, and the timing of,
necessary regulatory approvals; our ability to profitably sell our products at
prices that would be acceptable to third-party reimbursement programs;
competition including competition from others with significantly more
resources; market acceptance of our products and the size of our markets;
changes in business strategy or development plans; changes in, or the failure
to comply with, governmental regulations; fluctuations in interest rates and
foreign exchange rates; seasonality including government budget cycles;
general economic and business conditions where we operate; and other factors
referenced in our annual report on Form 20-F and other filings with Canadian
and United States securities regulatory authorities.
Given these uncertainties, assumptions and risks, readers are cautioned
not to place undue reliance on such forward-looking statements or information.
We disclaim any obligation to update, or to publicly announce any revisions
to, any such statements or information to reflect future results, events or
developments.